S100A9 and primary myelofibrosis: In this regard, considering that tasquinimod has been shown to ameliorate bone marrow fibrosis and splenomegaly in JAKV617F mice (43), it would be worth evaluating whether this S100A9 inhibitor is also able to block monocyte hyperactivation and lower cytokine levels in this model.